Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: A meta-analysis containing 8252 patients.

[1]  R. Jensen,et al.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies , 2019, Expert review of anticancer therapy.

[2]  Jennifer L Moseley,et al.  Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study , 2019, Clinical Cancer Research.

[3]  J. Cameron,et al.  Neutrophil-to-lymphocyte Ratio is a Predictive Marker for Invasive Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas , 2017, Annals of surgery.

[4]  D. Diamond,et al.  The pancreatic cancer microenvironment: A true double agent , 2017, Journal of surgical oncology.

[5]  P. Zhao,et al.  Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study , 2017, World Journal of Surgical Oncology.

[6]  Yusuke Yamamoto,et al.  Prognostic Scoring System for Patients Who Present with a Gastric Outlet Obstruction Caused by Advanced Pancreatic Adenocarcinoma , 2017, World Journal of Surgery.

[7]  Yan Shi,et al.  Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma , 2017, Scientific Reports.

[8]  Jie Chen,et al.  Neutrophil-lymphocyte ratio predicts survival in pancreatic neuroendocrine tumors. , 2017, Oncology letters.

[9]  Zuqiang Liu,et al.  Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer , 2017, Annals of Surgical Oncology.

[10]  Yong-jian Jiang,et al.  Role of immune cells in pancreatic cancer from bench to clinical application , 2016, Medicine.

[11]  T. Shichinohe,et al.  Clinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancer , 2016, World journal of gastrointestinal oncology.

[12]  J. Long,et al.  The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. , 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[13]  M. Morimoto,et al.  Duodenal stenting followed by systemic chemotherapy for patients with pancreatic cancer and gastric outlet obstruction. , 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[14]  M. Rutkowska,et al.  Preoperative Neutrophil-Lymphocyte and Lymphocyte-Monocyte Ratios Reflect Immune Cell Population Rearrangement in Resectable Pancreatic Cancer , 2016, Annals of Surgical Oncology.

[15]  J. García-Foncillas,et al.  Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis? , 2016, BioMed research international.

[16]  D. Xiu,et al.  Neutrophils assist the metastasis of circulating tumor cells in pancreatic ductal adenocarcinoma , 2016, Medicine.

[17]  E. Vasile,et al.  First‐line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors , 2016, International journal of cancer.

[18]  Zhen Chen,et al.  A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy , 2016, Cancer.

[19]  Jae Min Lee,et al.  Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. , 2016, World journal of gastrointestinal oncology.

[20]  Q. Zuo,et al.  The C-reactive protein/albumin ratio predicts overall survival of patients with advanced pancreatic cancer , 2016, Tumor Biology.

[21]  T. Misawa,et al.  Comprehensive assessment of the prognosis of pancreatic cancer: peripheral blood neutrophil–lymphocyte ratio and immunohistochemical analyses of the tumour site , 2016, Scandinavian journal of gastroenterology.

[22]  A. Miyamoto,et al.  Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer. , 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[23]  S. Jha,et al.  NLR-regulated pathways in cancer: opportunities and obstacles for therapeutic interventions , 2016, Cellular and Molecular Life Sciences.

[24]  N. Enomoto,et al.  Performance status and neutrophil-lymphocyte ratio are important prognostic factors in elderly patients with unresectable pancreatic cancer. , 2016, Journal of gastrointestinal oncology.

[25]  C. Thng,et al.  Preoperative platelet-to-lymphocyte ratio improves the performance of the international consensus guidelines in predicting malignant pancreatic cystic neoplasms. , 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[26]  Min Goo Lee,et al.  Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma , 2016, Cancer research and treatment : official journal of Korean Cancer Association.

[27]  H. Eguchi,et al.  Pre-treatment neutrophil to lymphocyte ratio as a predictive marker for pathological response to preoperative chemoradiotherapy in pancreatic cancer. , 2016, Oncology letters.

[28]  A. Matsuda,et al.  Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysis , 2016, Annals of Surgical Oncology.

[29]  M. Mizumoto,et al.  Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy , 2016, International Journal of Clinical Oncology.

[30]  Daniel T Chang,et al.  Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients With Pancreatic Adenocarcinoma Treated With SBRT , 2016, American journal of clinical oncology.

[31]  Y. Bang,et al.  More Accurate Prediction of Metastatic Pancreatic Cancer Patients’ Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity , 2016, PloS one.

[32]  M. Hiraoka,et al.  Pretreatment C-reactive protein level predicts outcome and patterns of failure after chemoradiotherapy for locally advanced pancreatic cancer. , 2015, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[33]  You Luo,et al.  Pretreatment Neutrophil to Lymphocyte Ratio as a Prognostic Predictor of Urologic Tumors , 2015, Medicine.

[34]  K. Shimizu,et al.  Preoperative neutrophil/lymphocyte ratio and prognostic nutritional index predict survival in patients with non-small cell lung cancer , 2015, World Journal of Surgical Oncology.

[35]  Qingtao Zhao,et al.  Prognostic role of neutrophil to lymphocyte ratio in lung cancers: a meta-analysis including 7,054 patients , 2015, OncoTargets and therapy.

[36]  Liu Yong-gang,et al.  The prognostic role of neutrophils to lymphocytes ratio and platelet count in gastric cancer: A meta-analysis. , 2015, International journal of surgery.

[37]  Zongguang Zhou,et al.  Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis , 2015, Scientific Reports.

[38]  Rong Liu,et al.  [Preoperative neutrophil-lymphocyte ratio as an independent prognostic predictor for pancreatic cancer]. , 2015, Zhonghua yi xue za zhi.

[39]  K. Paik,et al.  Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma , 2015, Medicine.

[40]  William H. Bisson,et al.  Environmental immune disruptors, inflammation and cancer risk. , 2015, Carcinogenesis.

[41]  Sheng-guang Yuan,et al.  Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis. , 2015, World journal of gastroenterology.

[42]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[43]  J. Jonkers,et al.  IL17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis , 2015, Nature.

[44]  Lifu Wang,et al.  Validation of the Pretreatment Neutrophil-Lymphocyte Ratio as a Predictor of Overall Survival in a Cohort of Patients With Pancreatic Ductal Adenocarcinoma , 2014, Pancreas.

[45]  S. Clarke,et al.  Cancer-related inflammation and treatment effectiveness. , 2014, The Lancet. Oncology.

[46]  M. Khattak,et al.  Prognostic value of systemic inflammation‐based markers in advanced pancreatic cancer , 2014, Internal medicine journal.

[47]  Zhengwen Liu,et al.  Prognostic role of neutrophil‐to‐lymphocyte ratio in colorectal cancer: A systematic review and meta‐analysis , 2014, International journal of cancer.

[48]  Shigemi Matsumoto,et al.  Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients , 2014, Cancer medicine.

[49]  P. Kornprat,et al.  External Validation of the Derived Neutrophil to Lymphocyte Ratio as a Prognostic Marker on a Large Cohort of Pancreatic Cancer Patients , 2013, PloS one.

[50]  M. Korc,et al.  Pancreatitis-Diabetes-Pancreatic Cancer: Summary of an NIDDK-NCI Workshop , 2013, Pancreas.

[51]  M. Teo,et al.  Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Advanced Pancreatic Ductal Adenocarcinoma: Impact of Baseline Fluctuation and Changes during Chemotherapy , 2013, Tumori.

[52]  P. Kornprat,et al.  Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer , 2013, British Journal of Cancer.

[53]  Darjus F. Tschaharganeh,et al.  Polymorphonuclear neutrophils promote dyshesion of tumor cells and elastase‐mediated degradation of E‐cadherin in pancreatic tumors , 2012, European journal of immunology.

[54]  P. Schirmacher,et al.  Epithelial-to-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma and Pancreatic Tumor Cell Lines: The Role of Neutrophils and Neutrophil-Derived Elastase , 2012, Clinical & developmental immunology.

[55]  Fenghua Wang,et al.  Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer , 2012, Medical Oncology.

[56]  A. Mantovani,et al.  Cancer-related inflammation: common themes and therapeutic opportunities. , 2012, Seminars in cancer biology.

[57]  V. Bhatt,et al.  Usefulness of the Neutrophil-to-Lymphocyte Ratio in Predicting Short- and Long-Term Mortality in Breast Cancer Patients , 2011, Annals of Surgical Oncology.

[58]  T. Keck,et al.  Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma , 2011, Angiogenesis.

[59]  X. An,et al.  Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer , 2010, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[60]  R. Hall,et al.  Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. , 2010, American journal of surgery.

[61]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[62]  Patrick Maisonneuve,et al.  Epidemiology of pancreatic cancer: an overview , 2009, Nature Reviews Gastroenterology &Hepatology.

[63]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[64]  C. Yeo,et al.  Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. , 2008, Journal of the American College of Surgeons.

[65]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[66]  S. Hirohashi,et al.  Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions , 2006, Clinical Cancer Research.

[67]  M. Plebani,et al.  Decreased Total Lymphocyte Counts in Pancreatic Cancer: An Index of Adverse Outcome , 2006, Pancreas.

[68]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[69]  G Bellone,et al.  Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. , 1999, The American journal of pathology.

[70]  J. Ross,et al.  Acute‐phase protein response and survival duration of patients with pancreatic cancer , 1995, Cancer.

[71]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[72]  F. Guadagni,et al.  Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin. , 2016, Cancer biomarkers : section A of Disease markers.

[73]  A. Saiura,et al.  Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a single institute in Japan. , 2015, Japanese journal of clinical oncology.

[74]  Zuqiang Liu,et al.  Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy , 2014, Annals of Surgical Oncology.

[75]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .